Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Natera, Inc. (NASDAQ: NTRA) presented new data on its Signatera test at the American Association for Cancer Research (AACR) meeting from April 14-19, 2023. The studies included findings on personalized MRD testing in various cancers, such as muscle-invasive bladder cancer and colorectal cancer. Key highlights include:
- Prediction of tumor response and recurrence using ctDNA in patients with esophago-gastric carcinoma and MIBC.
- Genomic profiling of more than 13,000 patients with colorectal cancer.
- ctDNA's potential to guide imaging-based surveillance for post-surgery patients.
- Data supporting ctDNA's role as a predictive biomarker in hepatocellular carcinoma.
These presentations emphasize Natera's commitment to advancing cancer care through innovative testing solutions.
Natera, Inc. (NASDAQ: NTRA) announced a study published in Cancer demonstrating the prognostic and predictive utility of its Signatera test for patients with stages III-IV melanoma. The study analyzed 555 plasma samples from 69 patients and revealed that MRD positivity post-surgery was linked to shorter distant metastasis-free survival (HR=10.77; p=0.01) and earlier detection of recurrence. Among unresectable patients, increasing ctDNA levels indicated shorter progression-free survival (HR=22; p=0.006). Signatera's accuracy in monitoring treatment response highlights its potential for personalized therapy decisions, addressing the unmet need for diagnostic tools in melanoma management.
Natera, Inc. (NASDAQ: NTRA) has announced significant advancements in commercial coverage for its Signatera molecular residual disease test. Effective March 1, 2023, Blue Shield of California will cover Signatera for all solid tumor patients, marking the company's first pan-cancer policy. Additionally, as of January 1, 2023, Blue Cross and Blue Shield of Louisiana will provide coverage for colorectal and bladder cancer monitoring. This underscores the medical necessity and enhanced access to Signatera testing, which has been validated through approximately 40 peer-reviewed publications for its efficacy in detecting cancer recurrence earlier than traditional methods.
Natera, Inc. (NASDAQ: NTRA) reported a robust performance for Q4 2022, achieving total revenues of $217.3 million, a 25.6% increase from Q4 2021. For the full year 2022, revenues reached $820.2 million, marking a 31.1% growth. The company processed approximately 559,700 tests in Q4 2022, up by 27.6% year-over-year, and over 2 million tests for the year, a 31.6% rise. However, gross margins declined to 41.4% in Q4 2022 from 45.6% in Q4 2021 due to higher costs. Looking ahead, Natera expects 2023 revenues between $980 million and $1 billion and aims to reduce cash burn by approximately $150 million.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, is set to present at two upcoming investor conferences. The first is the Raymond James 44th Annual Institutional Investors Conference on March 7 at 2:50 p.m. ET in Orlando, FL. The second is the Cowen 43rd Annual Health Care Conference on March 8 at 11:10 a.m. ET in Boston, MA. Live webcasts will be available on the Natera investor relations website, with replays accessible shortly after each event. Natera focuses on personalized genetic testing in oncology, women's health, and organ health, supported by over 100 peer-reviewed publications.